VRNA insider converts RSUs and options into $107/ADS cash
Rhea-AI Filing Summary
Reporting person Mahendra Shah, a director of Verona Pharma plc (VRNA), reported multiple transactions tied to the companys takeover by Merck. At the 10/07/2025 effective time of a Scheme of Arrangement, each American Depositary Share (ADS) entitled holders to $107 in cash, reflecting $13.375 per ordinary share times eight ordinary shares per ADS. Restricted share units and in-the-money options were accelerated and converted into cash payments under the transaction agreement. Following the transactions, the reporting person holds no ordinary shares or derivative securities of the issuer.
Positive
- Accelerated RSU vesting converted to cash at $107 per ADS, providing immediate liquidity
- In-the-money options were settled for cash per the agreement, allowing recovery of value without exercise risk
Negative
- Director no longer holds equity in the issuer following the Scheme (reported beneficial ownership is 0)
- Large disposals reported (e.g., 200,000, 240,000 options) removed potential future upside tied to the company
Insights
Director converted equity to cash under the takeover; holdings now zero.
The reported transactions show acceleration and cash settlement of equity awards at an $107 per-ADS consideration at the Schemes effective time on 10/07/2025. Time-based RSUs were treated as vested and converted to cash and certain in-the-money options yielded cash equal to the excess of the ADS consideration over exercise price.
This eliminates the directors ongoing equity exposure and crystallizes realized value; monitor any related lock-up terms or tax-withholding mechanics for timing of cash receipt and reporting, which may occur within days to weeks after the effective date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 200,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 96,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 240,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 64,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 93,472 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
